precisely: "when the science succeeds" the problem for IP now is facing a very good chance that prurisol science may not succeed at a time when the share price is so low- any current desperation stems from this. But of course it is not desperation, since it is just another buying opportunity
and the kevetrin science is on a far horizon- let's guess, 2020 before there is a trial starting to say yes or no if it actually has ANY benefit, and 2022 before results?
Market Data 
Markets 
AI
